Growth hormone secretion in critical illness: Effect of dopamine

Journal of Clinical Endocrinology and Metabolism

Volumn 79, Issue 4, 1994, Pages 1141-1146

  Van Den Berghe, Greet ^a,c   De Zegher, Francis ^a   Lauwers, Peter ^a   Veldhuis, Johannes D ^b  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY OF VIRGINIA   (United States)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; DOBUTAMINE; DOPAMINE; GROWTH HORMONE; HYDROCORTISONE; INSULIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CATABOLISM; CLINICAL ARTICLE; CRITICAL ILLNESS; DRUG MECHANISM; FEMALE; GROWTH HORMONE BLOOD LEVEL; GROWTH HORMONE RELEASE; HUMAN; MALE; MORBIDITY; MORTALITY; MULTIPLE TRAUMA; PRIORITY JOURNAL; PULSATILE HORMONE RELEASE;

ADOLESCENT; ADULT; AGED; CRITICAL ILLNESS; DOPAMINE; FEMALE; GROWTH HORMONE; HUMANS; HYDROCORTISONE; INFUSIONS, INTRAVENOUS; INSULIN; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; OSMOLAR CONCENTRATION; TIME FACTORS;

EID: 0027939146     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.79.4.1141     Document Type: Article

References (36)

1. Kinney JM, Elwyn DH. 1985 Protein metabolism in the traumatized patient. Acta Chir Scand. 522(Suppl):45-56.
2. Loder PB, Smith RC, Kee AJ, et al. 1990 What rate of infusion of intravenous nutrition solution is required to stimulate uptake of amino acids by peripheral tissues in depleted patients? Ann Surg. 211:360-368.
3. Wilmore DW. 1991 Catabolic illness. Strategies for enhancing recovery. N Engl J Med. 325:695-702.
4. Streat SJ, Beddoe AH, Hill GL. 1987 Aggressive nutritional support does not prevent protein loss despite fat gain in septic intensive care patients, J Trauma. 27:262-266.
5. Ross R, Miell J, Freeman E, et al. 1991 Critically ill patients have high basal growth hormone levels with attenuated oscillatory activity associated with low levels of insulin-like growth factor-1. Clin Endocrinol (Oxf). 35:7-54.
6. Kaplan SL. 1993 The newer uses of growth hormone in adults. In: Siperstein MD, ed. Advances in internal medicine. St Louis: Mosby Yearbook; vol 38:287-301.
7. Van den Berghe G, de Zegher F, Vanhaecke J, Verleden G, Lauwers P. Growth hormone as a rescue treatment after heart-lung or double lung transplantation. In press.
8. Edén S. 1979 Age and sex related differences in episodic growth hormone secretion in the rat. Endocrinology. 105:555-560.
9. Jansson JO, Albertson-Wikland K, Edén S, Thorngren KG, Isaksson OG. 1982 Effect of frequency of growth hormone administration on longitudinal bone growth and body weight in hypophysectomized rats. Acta Physiol Scand. 114:261-265.
10. Vermeulen A. 1987 Nyctohemeral growth hormone profiles in young and aged men: correlation with somatomedin-C-levels. J Clin Endocrinol Metab. 64:884-888.
11. Muller EE. 1987 Neural control of somatotropin function. Physiol Rev. 67:962-1053.
12. Goldberg LI. 1974 Dopamine-clinical uses of an endogenous catecholamine. N Engl J Med. 291:707-710.
13. Jarnberg PO, Bengtsson L, Ekstrand J, et al. 1981 Dopamine infusion in man: plasma catecholamine levels and pharmacokinetics. Acta Anaesthesiol Scand. 25:328-331.
14. Van den Berghe G, de Zegher F, Lauwers P. Dopamine and the euthyroid sick syndrome in critical illness. Clin Endocrinol (Oxf). In press.
15. Bouillon R, De Moor P. 1974 Heterogeneity of human growth hormone in serum. Ann Endocrinol (Paris). 35:606-613.
16. Verhaeghe J, Suiker AMH, Visser WJ, Van Herck E, Van Bree R, Bouillon R. 1992 The effects of systemic insulin, insulin-like growth factor 1 and growth hormone on bone growth and turnover in spontaneously diabetic BB-rats. J Endocrinol. 134:485-492.
17. Veldhuis JD, Covilson ML, Johnson ML. 1987 The pituitary gland secretes in bursts: appraising the nature of glandular secretory impulses by simultanuous multiple parameter deconvolution of plasma hormone concentrations. Proc Natl Acad Sci USA. 84:7686-7690.
18. Veldhuis JD, Johnson ML. 1992 Deconvolution analysis of pulsatile hormone data. Methods Enzymol. 210:539-575.
19. Faria ACS, Veldhuis JD, Thorner MO, Vance ML. 1989 Half-time of endogenous growth hormone disappearance in normal men after stimulation of GH secretion by GH releasing hormone and suppression with somatostatin. J Clin Endocrinol Metab. 68:535-541.
20. Hartman ML, Veldhuis JD, Johnson ML, et al. 1992 Augmented growth hormone (GH) secretory burst frequency and amplitude mediate enhanced GH secretion during a two-day fast in normal men. J Clin Endocrinol Metab. 74:757-765.
21. Voerman HJ, Strack van Schijnendel RJM, Groeneveld ABJ, de Boer H, Nauta JP, Thijs LG. 1992 Pulsatile hormone secretion during severe sepsis: accuracy of different blood sampling regimens. Metabolism. 41:934-940.
22. Woolf PD, Lantigua R, Lee LA. 1979 Dopamine inhibition of stimulated growth hormone secretion: evidence for dopaminergic modulation of insulin and L-dopa induced growth hormone secretion in man. J Clin Endocrinol Metab. 49:326-330.
23. Bansal SA, Lee LA, Woolf PD. 1981 Dopaminergic stimulation and inhibition of growth hormone secretion in normal man: studies on the pharmacological specificity. J Clin Endocrinol Metab. 53:1273-1277.
24. Thorner MO, Chait A, Aitken M, et al. 1975 Bromocriptine treatment of acromegaly. Br Med J. 1:299-303.
25. de Zegher F, Van den Berghe G, Devlieger H, Eggermont E, Veldhuis JD. 1993 Dopamine inhibits growth hormone and prolactin secretion in the human newborn. Pediatr Res. 34:642-645.
26. Vance ML, Kaiser DL, Frohman LA, Rivier J, Vale WW, Thorner MO. 1987 Role of dopamine in the regulation of growth hormone secretion: dopamine and bromocriptine augment growth hormone-releasing hormone stimulated GH secretion in normal man. J Clin Endocrinol Metab. 64:1136-1141.
27. Marcovitz S, Goodyer CG, Guyda H, Gardiner RJ, Hardy S. 1982 Comparative study of human fetal, normal adult, and somatotropic adenoma pituitary function in tissue culture. J Clin Endocrinol Metab. 54:6-16.
28. Wood DF, Johnston JM, Johnston DG. 1991 Dopamine, the dopamine D2 receptor and pituitary tumours. Clin Endocrinol (Oxf). 35:455-466.
29. Hartman ML, Faria ACS, Vance ML, Johnson ML, Thorner MO, Veldhuis JD. 1991 Temporal structure of in vivo growth hormone secretory events in man. Am J Physiol. 260:E101-E110.
30. Berelowitz M, Szabo M, Frohman LA, Firestone S, Chu L, Hintz RL. 1985 Somatomedin-C mediates growth hormone negative feedback by effects on both the hypothalamus and the pituitary. Science. 230:461-463.
31. Ross RJM, Miell JP, Holly JMP, et al. 1991 Levels of GH-binding activity, IGFBP-1, insulin, blood glucose and cortisol in intensive care patients. Clin Endocrinol (Oxf). 35:361-367.
32. Yamashita S, Melmed S. 1986 Effects of insulin on rat anterior pituitary cells: inhibition of GH secretion and mRNA levels. Diabetes. 35:440-447.
33. Blethen SL, Daughaday WH, Weldon V. 1982 Kinetics of the somatomedin-C insuline-like growth factor I. Response to exogenous growth hormone (GH) in GH-deficient children. J Clin Endocrinol Metab. 54:986-990.
34. Horber FF, Haymond MV. 1990 Human growth hormone prevents the protein catabolic side-effects of prednisone in humans. J Clin Invest. 86:265-272.
35. Clemmons DR, Snyder DK, Williams R, Underwood LE. 1987 Growth hormone administration conserves lean body mass during dietary restriction in obese subjects. J Clin Endocrinol Metab. 64:878-883.
36. Kupfer SR, Underwood, Baxter RC, Clemmons DR. 1993 Enhancement of the anabolic effects of growth hormone and insulin-like growth factor-1 by use of both agents simultanuously. J Clin Invest. 91:391-396.